

1 **SARS-CoV-2 infection- induced seroprevalence among**  
2 **children and associated risk factors during pre- and**  
3 **omicron-dominant wave, from January 2021 through**  
4 **November 2022, Thailand: Longitudinal study**

5  
6 Nungruthai Suntronwong<sup>1</sup>, Preeyaporn Vichaiwattana<sup>1</sup>, Sirapa Klinfueng<sup>1</sup>, Jiratchaya Puenpa<sup>1</sup>,  
7 Sitthichai Kanokudom<sup>1,2</sup>, Suvichada Assawakosri<sup>1,2</sup>, Jira Chansaenroj<sup>1</sup>, Donchida Srimuan<sup>1</sup>,  
8 Thaksaporn Thatsanatorn<sup>1</sup>, Siriporn Songtaisarana<sup>1</sup>, Natthinee Sudhinaraset<sup>1</sup>, Nasamon  
9 Wanlapakorn<sup>1</sup>, Yong Poovorawan<sup>1,3\*</sup>

10 <sup>1</sup> Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University,  
11 Bangkok 10330, Thailand

12 <sup>2</sup> Center of Excellence in Osteoarthritis and Musculoskeleton, Faculty of Medicine,  
13 Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society,  
14 Bangkok, 10330, Thailand

15 <sup>3</sup> The Royal Society of Thailand (FRS(T)), Sanam Sueapa, Dusit, Bangkok 10330, Thailand.

16

17 \*Corresponding author

18 Email: [yong.p@chula.ac.th](mailto:yong.p@chula.ac.th)

19

20

## 21 **Abstract**

### 22 **Background**

23 Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection can be  
24 asymptomatic in young children. Therefore, the true rate of infection is likely underestimated.  
25 Few data are available on the rate of infections in young children, and studies on the SARS-  
26 CoV-2 seroprevalence among children during omicron wave are limited. Our study aims to  
27 assess the SARS-CoV-2 infection-induced seroprevalence among children and estimated the  
28 associated risk factors for seropositivity.

### 29 **Methods**

30 A longitudinal serological survey was conducted from January 2021 through November  
31 2022. Samples were tested for anti-nucleocapsid (N) IgG, anti-receptor binding domain (RBD)  
32 IgG using a chemiluminescent microparticle immunoassay (CMIA) and detected anti-RBD  
33 Immunoglobulin (Ig) using an electrochemiluminescence immunoassay (ECLIA). The  
34 vaccination and SARS-CoV-2 infection history were collected.

### 35 **Results**

36 A total of 452 serum samples were obtained from 249 children aged 5–7 years old who  
37 were annually followed-up in the longitudinal serological survey. Of these, 191 participants  
38 provided samples at two serial time points, including during the pre-and omicron dominant  
39 wave. Overall, seroprevalence induced by SARS-CoV-2 infection was increased from 9.1%  
40 (95%CI: 0.6-12.6%) during the pre-omicron wave to 49.7% (95%CI: 35.9-66.8%) during the  
41 omicron wave. Amongst seropositive individuals, the infection-induced seroprevalence was  
42 lower in vaccinated participants than those with no vaccination (40.4% vs. 57.4%; risk ratio,

43 0.71; 95%CI: 0.52–0.95). Nevertheless, the ratio of seropositive cases per recalled infection was  
44 1.56 during the omicron dominant wave. In addition, overall seroprevalence induced by  
45 infection, vaccination and hybrid immunity was 76.6% (151/197; 95%CI: 54.6-97.9%) between  
46 January and November 2022.

47

## 48 **Conclusions**

49 our study reports an increase in infection-induced seroprevalence among children during  
50 the omicron wave. These findings highlight that estimating seroprevalence is crucial to monitor  
51 SARS-CoV-2 exposure, particularly in asymptomatic infection, and help to optimize public  
52 health policies and determine the effect of immunization in the pediatric population.

53

54 **Keywords:** SARS-CoV-2, Seroprevalence, Children, Omicron variant

55

56

57

58

59

60

61

62

63

64

65

## 66 Introduction

67 Most children with SARS-CoV-2 infection are asymptomatic at presentation. Thus,  
68 mildly symptomatic and asymptomatic children might not be tested for or diagnosed with SARS-  
69 CoV-2 infection [1]. As a result, pediatric COVID-19 cases are underestimated and likely higher  
70 than reported according to the reverse transcriptase-polymerase chain reaction (RT-PCR) results.  
71 Furthermore, children are commonly infected after close contact with other members in the same  
72 household. They are likely unaware of their infection status, potentially contributing to virus  
73 transmission [2].

74 Although children with COVID-19 typically develop a milder illness than adults, long-  
75 term complications including multisystem inflammatory syndrome in children (MIS-C) can  
76 occur after SARS-CoV-2 infection [3]. Recent evidence notes that COVID-19 vaccination in  
77 children is associated with a high level of protection against MIS-C and a reduced rate of  
78 hospitalization and deaths [4]. In Thailand, the Thai Food and Drugs Administration have  
79 approved BNT162b2 for vaccination in children aged 5–11 years old, and CoronaVac and  
80 BBIBP-CorV for children aged  $\geq 6$  years old. Consequently, data on seroprevalence in children is  
81 essential to inform and guide vaccine policies.

82 The value of a serological survey is the retrospective detection of individuals who had a  
83 previous infection, even in an asymptomatic case, which helps monitor virus transmission [5].  
84 Anti-nucleocapsid (N) and anti-receptor binding domain (RBD) antibodies are elicited after  
85 natural infection or vaccination. However, anti-N antibodies can detect after receipt the  
86 inactivated vaccine but not detected after receipt of the virus vector or mRNA vaccines.  
87 Moreover, some Thai children could elicit anti-N IgG because of being vaccinated with an  
88 inactivated vaccine. Consequently, the detection of anti-N and anti-RBD antibodies in

89 unvaccinated individuals and anti-N antibodies in vaccinated individuals with mRNA vaccines  
90 could estimate the proportion of individuals who have been infected with SARS-CoV-2. In  
91 addition, serological surveys can inform the impact of immunization on the population.

92           Omicron was first detected in Thailand in mid-December 2021. The incidence of omicron  
93 infection rapidly increased and subsequently became the predominant variant by January 2022  
94 [6]. Study demonstrated that the omicron variant is highly transmissible and can evade the  
95 immune system even in vaccinated or previously infected individuals [7]. In line with this, the  
96 spreading of omicron variants peaked between January and March 2022. In addition, infection by  
97 the omicron variant resulted in milder symptoms and was associated with lower risks of  
98 hospitalization and death than the delta variant [8]. However, few data are available on the rate  
99 of infections in young children, and studies on the SARS-CoV-2 seroprevalence among children  
100 during omicron wave are limited.

101           In this study, we assessed the seroprevalence of anti-SARS-CoV-2 antibodies induced by  
102 SARS-CoV-2 infection from January 2021 to November 2022 (the duration spanned the pre- and  
103 omicron wave) and estimated the associated risk factors for seropositivity. Data on  
104 seroprevalence can help to estimate the number of children who experience SARS-CoV-2  
105 infection and assess the impact of immunization on protect SARS-CoV-2 infection in pediatric  
106 population which is paramount to establish public health prevention and vaccination strategies.

107

108

109

## 110 **Materials and methods**

## 111 **Study design and sample collection**

112           This study analyzed the serum samples from children who were followed-up in the  
113 longitudinal serological study of pertussis vaccine immunity at the Center of Excellence in  
114 Clinical Virology, Chulalongkorn Memorial Hospital, Bangkok, Thailand, from January 1, 2021  
115 through November 9, 2022 [9]. Participants were invited to complete surveys on SARS-CoV-2  
116 infection and COVID-19 vaccination. This survey included questions regarding previous SARS-  
117 CoV-2 infections detected by RT-PCR test or antigen test kit (ATK); date of infection; and  
118 vaccination data, including type, dose, and date of vaccination, as reported by the children's  
119 parents. The survey responses were retrospectively collected between May and November 2022.  
120 The inclusion criteria were the same as the longitudinal serological study of the pertussis vaccine  
121 immunity. However, the exclusion criteria were parents who did not want to disclose vaccination  
122 and infection history, and children who previously received any dose of the inactivated COVID-  
123 19 vaccine, because such individuals could elicit anti-N IgG from the inactivated vaccine.

124           The Research Ethics Committee of the Faculty of Medicine, Chulalongkorn University  
125 approved the study (IRB number: 173/63). The study protocol adhered to the tenets of the  
126 Declaration of Helsinki and Good Clinical Practice principles. Written informed consent was  
127 obtained from the parents or legal guardians of all participating children.

128

## 129 **Serological analysis**

130           Sera samples collected from eligible participants were subjected to IgG-specific testing  
131 against SARS-CoV-2 nucleocapsid (N) protein using a chemiluminescent microparticle  
132 immunoassay (CMIA) (Abbott Architect Immunoassay; Abbott Diagnostics, Abbott Park, IL,  
133 USA). According to the manufacturer's instructions, we considered samples with a signal-to-cut-

134 off ratio  $\geq 1.4$  as anti-N IgG positive, while samples with a value  $< 1.4$  was considered as  
135 seronegative. The total immunoglobulin (Ig) and IgG specific against SARS-CoV-2 receptor  
136 binding domain (RBD) quantitatively measured using the Roche Elecsys anti-SARS-CoV-2  
137 immunoglobulin immune assay (Roche) and SARS-CoV-2 Quant IgG II (Abbott Diagnostics,  
138 Abbott Park, IL, USA), respectively. Antibody level is expressed as U/mL for anti-RBD Ig, with  
139 a cut-off  $\geq 0.8$  defined as positive and BAU/mL for anti-RBD IgG, with values  $\geq 7.1$  scored  
140 positive.

141

## 142 **Classify the samples with seropositivity**

143 Infection-induced seropositivity was estimated based on the presence of anti-RBD Ig ( $\geq$   
144 0.8 U/mL), anti-RBD IgG ( $\geq 7.1$  BAU/mL) or anti-N IgG ( $\geq 1.4$  S/C) among unvaccinated  
145 children and the presence of anti-N IgG or having an evidence of SARS-CoV-2 infection during  
146 omicron variants in vaccinated individuals with BNT162b2 vaccine. Vaccination status was  
147 classify according to the dates of reported infection and vaccination. Overall seroprevalence  
148 induced by infection, vaccination, and hybrid immunity was estimated based on the anti-RBD  
149 antibody seropositivity in both unvaccinated and vaccinated participants.

150

## 151 **Statistical analysis**

152 Data are mainly presented as numbers and percentages. The primary outcome was  
153 infection-induced seroprevalence. Risk ratios associated with infection-induced seropositivity  
154 and demographic characteristics were calculated using the chi-square test. The ratio of children  
155 with infection-induced seropositivity during the omicron dominant wave per recalled of previous  
156 SARS-CoV-2 infection were assessed. Statistical analysis was conducted using SPSS v23.0

157 (IBM Corp, Armonk, NY, USA). A  $p$ -value  $<0.05$  was considered to indicate statistically  
158 significant differences.

159

## 160 **Results**

### 161 **Study participants**

162 There were 452 samples from 249 participants enrolled in the source study (Fig 1). Of  
163 these, 241 samples were collected from January through December 2021 (hereafter referred to as  
164 the pre-omicron wave), and 211 samples were collected from January to November 2022  
165 (hereafter referred to as the omicron-dominant wave). Between January and November 2022,  
166 two participants were excluded because they lacked vaccination history, and 12 participants were  
167 excluded because they received an inactivated vaccine. Thus, 438 serum samples from 247  
168 participants were eligible and met the criteria for the final analysis.

169 In total, 438 samples were obtained, including 55% (241/438) serum samples collected  
170 between January and December 2021 and 45% (197/438) collected between January and  
171 November 2022, during which time omicron was predominantly circulating. The mean (SD) age  
172 of study participants enrolled during pre- and omicron wave was 5.12 (0.34) and 6.16 (0.36)  
173 years old, and there were 51% female and 49% male subjects (S1 Table). Of these, 191  
174 participants provided samples at two serial time points, including during the pre-and omicron  
175 dominant wave, and the median interval between the two blood samplings was 362 days (IQR:  
176 343–376). During the omicron-dominant wave, 45.2% (89/197) of participants received at least  
177 one dose of BNT162b2 by February 2022 included 42.7% (38/89), 55.1% (49/89) and 2.2%  
178 (2/89) of participants who had been received a single dose, two-doses and three doses of



179 BNT162b2, respectively, while no participant enrolled during the pre-omicron wave received the  
180 COVID-19 vaccine.

181

## 182 **Seroprevalence induced by SARS-CoV-2 infection**

183 There were 120 samples out of a total of 438 that tested anti-RBD Ig or anti-N IgG  
184 seropositive for unvaccinated participants and anti-N IgG seropositive or having reported of  
185 SARS-CoV-2 infection during omicron for vaccinated participants, resulting in an estimated  
186 infection-induced seroprevalence of 27.4% (95%CI: 15.7–40.3%) (Fig 2). The infection-induced  
187 seroprevalence increased from 9.1% (95%CI: 0.6–12.6%) for January to December 2021 to  
188 49.7% (95%CI: 35.9–66.8%) observed between January and November 2022. Amongst  
189 seropositive participants during the pre-omicron wave, 14 participants were follow-up the  
190 serological cohorts during the omicron-dominant wave and 87.5 % (14/16) of children were  
191 provided evidence of re-infection.

192

## 193 **Factors associated with infection-induced seropositivity**

194 Among unvaccinated participants, samples collected during the omicron dominant wave  
195 were more likely seropositive than those collected during the pre-omicron wave (57.4% vs.  
196 9.1%; risk ratio, 6.29; 95%CI: 4.09–9.67,  $p < 0.001$ ) (Table 1). Notably, vaccinated participants  
197 was less likely infected with SARS-CoV-2 than unvaccinated participants (40.4% vs. 57.4%; risk  
198 ratio, 0.71; 95%CI: 0.52–0.95;  $p < 0.05$ ) and participants vaccinated with two-doses of BNT162b2  
199 were associated with a low seroprevalence than those immunized with a single dose (24.5% vs.  
200 63.2%; risk ratio, 0.39; 95%CI: 0.22–0.67,  $p < 0.001$ ). There was no difference in seroprevalence  
201 rate between participants living in a household with  $\geq 5$  members and those living in a household

202 with <5 members during the omicron wave. However, children living with household members  
 203 who had previous COVID-19 infection had a higher risk of seropositivity than those living with  
 204 household members without SARS-CoV-2 infection (73.7% vs.21.1%; risk ratio, 3.45; 95%CI:  
 205 2.19–5.55; P<0.001).

206

207 **Table 1.** SARS-CoV-2 infection-induced seropositivity and risk factors for seropositivity.

Characteristic	Overall	Infection-induced seroprevalence		Risk ratio associated with seropositivity, Risk ratio (95%CI)
	n	n	(%)	
Overall	438	120	27.4%	-
-Pre-omicron wave	241	22	9.1%	Ref
-Omicron dominant wave	197	98	49.7%	5.45 (3.57–8.31)***
Sex, n (%) according to the study period				
Pre-omicron wave				
Boy	117	12	10.3%	Ref
Girl	124	10	8.1%	0.79 (0.35–1.75)
Omicron-dominant wave				
Boy	96	49	51.0%	Ref
Girl	101	49	48.5%	0.95 (0.72–1.26)

Vaccination status according to dates of infection and vaccination				
Unvaccinated				
Pre-omicron wave	241	22	9.1%	Ref
Omicron-dominant wave	108	62	57.4%	6.29 (4.09–9.67) ***
Omicron dominant wave (n=197)				
Unvaccinated	108	62	57.4%	Ref*
Vaccination	89	36	40.4%	0.71 (0.52–0.95)
Dose of vaccine				
-BNT162b2 (1 dose)	38	24	63.2%	Ref
-BNT162b2 (2 doses)	49	12	24.5%	0.39 (0.22–0.67)***
-BNT162b2 (3 doses)	2	0	0%	-
Pre-omicron wave				
Number of household members, n				
2–4	96	4	4.2%	Ref
≥5	62	12	19.4%	4.65 (1.57-13.76)**

N/A	83	6	7.2 %	-
<b>Omicron-dominant wave</b>				
Number of household members, n				
2–4	100	50	50.0%	Ref
≥5	64	35	54.7%	1.01 (0.81–1.47)
N/A	33	13	39.4%	-
<b>Confirmed COVID-19 infection in household members tested via PCR or ATK during the omicron wave, n</b>				
No	71	15	21.1%	Ref
Yes	95	70	73.7%	3.45 (2.19–5.55)***
N/A	31	13	41.9%	-

208 Statistical analysis was performed using the chi-square test. \* indicates  $p < 0.05$ , \*\*\*indicates  
 209  $p < 0.001$  \*\*\*indicates  $p < 0.001$ .

210

### 211 **Infection-induced seropositivity associated with previous SARS-CoV-2 testing**

212 We further estimated the ratio of infection-induced seropositive cases per recalled  
 213 infection during the omicron dominant wave. Overall, 89.4% (176/197) participants completed a  
 214 survey on infection history. Subsequently, 92 of 176 children showed infection-induced  
 215 seropositivity. Of these, 64.1% (59/92) previously reported SARS-CoV-2 infection, and the

216 median interval between dates of infection and blood collection was 95 days (IQR: 64–175),  
217 while 35.9% (33/92) reported being unaware of their infection status (Table 2). Therefore, the  
218 ratio of infection-induced seropositive cases per recalled infection during omicron was 1.56  
219 (92/59). Moreover, only 4.3% (4/94) seronegative participants reported previous SARS-CoV-2  
220 infection, for which the median interval between infection and blood collection dates was 311  
221 days (IQR: 272.5–316.5).

222

223 **Table 2 Association between infection-induced seropositivity and previous SARS-CoV-2**  
224 **infection.** Number of children who complete a survey of infection history (n=176) and infection-  
225 induced seropositivity during the omicron-dominant wave (January–November 2022).

226

	Infection-induced seropositive (n=92)	Infection-induced seronegative (n=94)
History of previous infection (n=63)	59	4
Interval between the reported date of infection and blood collection, median (IQR)	95 (64–175)	311 (272.5–316.5)
No history of previous infection (n=113)	33	80

227 Previous SARS-CoV-2 infection was diagnosed by RT-PCR or ATK test

228

## 229 **Seroprevalence induced by infection, vaccination and hybrid**

### 230 **immunity**

231 We further estimated the overall seroprevalence induced by natural infection, vaccination  
232 and hybrid immunity based on the seropositivity of anti-RBD antibodies (Fig 3). Regarding the  
233 vaccine implementation in children, the seropositivity of anti-RBD antibodies was 76.6%  
234 (151/197; 95%CI: 54.6-97.9%) between January and November 2022 which increased by Mar  
235 2022 and reached greater than 80% (95%CI: 88.6-96.2%) since April 2022.

236

## 237 **Discussion**

238 Our findings report the increase in seroprevalence induced by infection among children  
239 from January through November 2022, indicating the high rates of SARS-CoV-2 infection  
240 during the omicron wave. This is in agreement with other studies that have reported a significant  
241 rise in the seroprevalence rate among children during the omicron wave in South Africa [10] and  
242 the United States [11]. This finding supported the previous report which showed that the omicron  
243 variant is more transmissible than the previous SARS-CoV-2 variants [7].

244 Our results also showed that even children who received the BNT162b2 vaccine were  
245 anti-N IgG seropositive during the omicron wave. This result might be related to the antibody  
246 evasion by omicron variants and the limit of vaccine efficacy among children [12]. Although  
247 vaccinated children were susceptible to being infected by the omicron variant, the risks of  
248 infection and hospitalization were reduced for vaccinated compared to unvaccinated children

249 aged between 5 and 11 years [13]. In addition, our study showed that vaccinated children with  
250 two-dose vaccines were less likely to be seropositive than those who were vaccinated with a  
251 single dose. This result was supported by a meta-analysis study that suggested that the estimated  
252 mean secondary attack rates observed during the omicron wave were higher in partially  
253 vaccinated cases (76.8%, 95%CI: 7.7%–99.2%) than in fully vaccinated cases (50.8%, 95%CI:  
254 47.9%–53.8%) [14].

255 Although an increased number of household members did not affect the risk of  
256 seropositivity in children, we found a higher risk of seropositivity was observed in children  
257 living with infected household members than those living with non-infected household members.  
258 This finding was consistent with a study from Switzerland that indicated the risk of being  
259 seropositive in children aged <6 years was more likely associated with the number of household  
260 members who tested positive for SARS-CoV-2, indicating the SARS-CoV-2 transmission for  
261 children aged <6 years occurs commonly within the family [15].

262 The proportion of anti-N IgG or anti-RBD antibody seropositive among unvaccinated and  
263 anti-N IgG seropositive among vaccinated cases may reflect the true rate of infections, including  
264 mildly symptomatic or asymptomatic cases and undetected by COVID-19 testing. Our study  
265 found that 35.9% children aged 5–7 years with seropositivity reported no previous infection.  
266 This result may reflect either asymptomatic infection or undetected infection upon COVID-19  
267 testing in patients likely unaware of their infection status, in which case the virus remains  
268 actively transmissible [16]. In addition, our estimated ratio of seropositive cases per recall  
269 infection was lower than that reported in a seroprevalence study in children aged 3–11 years  
270 from Germany between March and May 2021 (1.56 vs. 3.0) [17] and another study of awareness  
271 in adults during the omicron wave (1.56 vs. 2.28) [5].

272           The anti-N IgG seronegative results in children that reported infection may be owing to  
273 the long interval from infection to blood sampling and the severity of disease after infection. This  
274 result was supported by a previous study in adults indicating that 87.5% individuals had  
275 detectable the anti-N IgG even 3 months post-infection, while only 26.6% individuals had  
276 detectable the anti-N IgG 12 months post-infection [18]. In addition, recent evidence showed that  
277 the sensitivity of anti-N IgG detection among individuals with recent infection defined by RT-  
278 PCR testing ranged from 74% to 81% during the omicron wave [19]. To overcome the limitation  
279 of anti-N IgG detection, our study included anti-RBD antibodies to classify the seropositivity  
280 induced by SARS-CoV-2 infection in unvaccinated participants and be considered evidence of  
281 SARS-CoV-2 infection in vaccinated participants.

282           The limitations of the study include the small sample size, as this may not represent the  
283 seroprevalence in the general population. Further, the present study could have underestimated  
284 the cumulative seropositivity because children with inactivated vaccines were not included.  
285 Furthermore, anti-N antibody titers waned over time, and the sensitivity of the anti-N IgG assay  
286 to detect the antibody was dependent on the time between the infection and blood collection and  
287 vaccination status [20].

288           In conclusion, our study reports an increase in infection-induced seroprevalence among  
289 children during the omicron wave and overall seroprevalence induced by natural infection,  
290 vaccination and hybrid immunity. This shows that the benefit of anti-SARS-CoV-2 antibody  
291 detection can help to assess the seroprevalence induced by infection which subsequently track  
292 the transmission of SARS-CoV-2 variants and determine the effect of immunization in the  
293 pediatric population.

294



295 **Acknowledgments:** We would like to thank all the staff of the Center of Excellence in Clinical  
296 Virology. This research was financially supported by the Health Systems Research Institute  
297 (HSRI), National Research Council of Thailand (NRCT), the Center of Excellence in Clinical  
298 Virology, Chulalongkorn University, and King Chulalongkorn Memorial Hospital, MK  
299 Restaurant Group Aunt Thongkam Foundation, BJC Big C Foundation, and the Second Century  
300 Fund (C2F), Chulalongkorn University.

301  
302 **Author Contributions:** Conceptualization, N.S.(Nungruthai Suntronwong), N.W. and Y.P.; data  
303 curation, N.S. (Nungruthai Suntronwong), J.P., D.S., T.T., S.S., and N.S. (Natthinee  
304 Sudhinaraset); formal analysis, N.S.(Nungruthai Suntronwong); methodology, P.V., S.K. (Sirapa  
305 Klinfueng), S.K. (Sitthichai Kanokudom), S.A., and J.C.; project administration, Y.P.; writing—  
306 original draft, N.S. (Nungruthai Suntronwong); writing—review and editing, N.S. (Nungruthai  
307 Suntronwong), S.K. (Sitthichai Kanokudom), N.W., and Y.P. All authors have read and agreed  
308 to the published version of the manuscript.

309  
310 **Financial Disclosure**

311 This work was supported by the National Research Council of Thailand, the Health Systems  
312 Research Institute, the Center of Excellence in Clinical Virology of Chulalongkorn  
313 University, King Chulalongkorn Memorial Hospital, and the Berli Jucker Company Big C  
314 foundation. Nungruthai Suntronwong reports that financial support was also provided by the  
315 Second Century Fund Fellowship of Chulalongkorn University. The funders had no role in study  
316 design, data collection and analysis, decision to publish, or preparation of the manuscript.

317

318 **Institutional Review Board Statement:** The study protocol was approved by the Research  
319 Ethics Committee of the Faculty of Medicine, Chulalongkorn University (IRB number: 173/63).  
320 The study protocol adhered to the tenets of the Declaration of Helsinki and Good Clinical  
321 Practice principles. Written informed consent was obtained from the parents or legal guardians of  
322 all participating children.

323

324 **Data Availability Statement:** All relevant data are within the manuscript and its Supporting  
325 Information files.

326

327 **Declaration of Competing Interests:** The authors have declared that no competing interests exist.

328

## 329 **References**

- 330 1. Karron RA, Hetrich MK, Na YB, Knoll MD, Schappell E, Meece J, et al. Assessment of  
331 Clinical and Virological Characteristics of SARS-CoV-2 Infection Among Children  
332 Aged 0 to 4 Years and Their Household Members. *JAMA Netw Open*  
333 2022;5(8):e2227348. Doi: 10.1001/jamanetworkopen.2022.27348.
- 334 2. Stein-Zamir C, Abramson N, Shoob H, Libal E, Bitan M, Cardash T, et al. A large  
335 COVID-19 outbreak in a high school 10 days after schools' reopening, Israel, May 2020.  
336 *Euro Surveill* 2020;25(29):2001352. Doi: 10.2807/1560-7917.ES.2020.25.29.2001352.
- 337 3. Pierce CA, Herold KC, Herold BC, Chou J, Randolph A, Kane B, et al. COVID-19 and  
338 children. *Science* 2022;377(6611):1144-1149. Doi: 10.1126/science.ade1675.
- 339 4. Zambrano LD, Newhams MM, Olson SM, Halasa NB, Price AM, Boom JA, et al.  
340 Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem

- 341 Inflammatory Syndrome in Children Among Persons Aged 12-18 Years – United States,  
342 July-December 2021. *MMWR Morb Mortal Wkly Rep* 2022;71(2):52-58. Doi:  
343 10.15585/mmwr.mm7102e1.
- 344 5. Joung SY, Ebinger JE, Sun N, Liu Y, Wu M, Tang AB, et al. Awareness of SARS-CoV-2  
345 Omicron Variant Infection Among Adults With Recent COVID-19 Seropositivity. *JAMA*  
346 *Netw Open* 2022;5(8):e2227241. Doi: 10.1001/jamanetworkopen.2022.27241.
- 347 6. Puenpa J, Rattanakomol P, Saengdao N, Chansaenroj J, Yorsaeng R, Suwannakarn K et  
348 al. Molecular characterization and tracking of the severe acute respiratory syndrome  
349 coronavirus 2, Thailand, 2020–2022. *Research Square* 2022. Doi:  
350 <https://doi.org/10.21203/rs.3.rs-1545056/v1>.
- 351 7. Jalali N, Brustad HK, Frigessi A, MacDonald EA, Meijerink H, Feruglio SL, et al.  
352 Increased household transmission and immune escape of the SARS-CoV-2 Omicron  
353 compared to Delta variants. *Nat Commun* 2022;13(1):5706. Doi: 10.1038/s41467-022-  
354 33233-9.
- 355 8. Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SY. Clinical outcomes  
356 associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2  
357 subvariant infection in Southern California. *Nat Med* 2022;28(9):1933-1943. Doi:  
358 10.1038/s41591-022-01887-z.
- 359 9. Wanlapakorn N, Maertens K, Vongpunsawad S, Puenpa J, Tran TMP, Hens N, et al.  
360 Quantity and Quality of Antibodies After Acellular Versus Whole-cell Pertussis Vaccines  
361 in Infants Born to Mothers Who Received Tetanus, Diphtheria, and Acellular Pertussis  
362 Vaccine During Pregnancy: A Randomized Trial. *Clin Infect Dis* 2020;71(1):72-80. Doi:  
363 10.1093/cid/ciz778.

- 364 10. Madhi SA, Kwatra G, Myers JE, Jassat W, Dhar N, Mukendi CK, et al. Population  
365 Immunity and Covid-19 Severity with Omicron Variant in South Africa. *N Engl J Med*  
366 2022;386(14):1314-1326. Doi: 10.1056/NEJMoa2119658.
- 367 11. Clarke KEN, Jones JM, Deng Y, Nycz E, Lee A, Iachan R, et al. Seroprevalence of  
368 Infection-Induced SARS-CoV-2 Antibodies – United States, September 2021-February  
369 2022. *MMWR Morb Mortal Wkly Rep* 2022;71(17):606-608. Doi:  
370 10.15585/mmwr.mm7117e3.
- 371 12. Katz SE, Edwards K. Protecting Children Against Omicron. *JAMA* 2022;327(22):2195-  
372 2197. Doi: 10.1001/jama.2022.7315.
- 373 13. Dorabawila V, Hoefler D, Bauer UE, Bassett MT, Lutterloh E, Rosenberg ES. Risk of  
374 Infection and Hospitalization Among Vaccinated and Unvaccinated Children and  
375 Adolescents in New York After the Emergence of the Omicron Variant. *JAMA*  
376 2022;327(22):2242-2244. Doi: 10.1001/jama.2022.7319.
- 377 14. Madewell ZJ, Yang Y, Longini IM Jr, Halloran ME, Dean NE. Household Secondary  
378 Attack Rates of SARS-CoV-2 by Variant and Vaccination Status: An Updated  
379 Systematic Review and Meta-analysis. *JAMA Netw Open* 2022;5(4):e229317. Doi:  
380 10.1001/jamanetworkopen.2022.9317.
- 381 15. Rouge Elton PA, Schmitt PA, Faouzi M, Zimmermann P, Ritter Schenk C.  
382 Seroprevalence of SARS-CoV-2 antibodies and associated risk factors in children less  
383 than 6 years of age in the canton of Fribourg, Switzerland (COVPED study): a  
384 population-based cross-sectional study. *Swiss Med Wkly* 2022;152:w30173. Doi:  
385 10.4414/smw.2022.w30173.

- 386 16. Kim EY, Choe YJ, Park H, Jeong H, Chung JH, Yu J, et al. Community Transmission of  
387 SARS-CoV-2 Omicron Variant, South Korea, 2021. *Emerg Infect Dis.* 2022  
388 Apr;28(4):898-900. Doi: 10.3201/eid2804.220006.
- 389 17. Sorg AL, Bergfeld L, Jank M, Corman V, Semmler I, Goertz A, et al. Cross-sectional  
390 seroprevalence surveys of SARS-CoV-2 antibodies in children in Germany, June 2020 to  
391 May 2021. *Nat Commun* 2022;13(1):3128. Doi: 10.1038/s41467-022-30482-6.
- 392 18. Chansaenroj J, Yorsaeng R, Posuwan N, Puenpa J, Wanlapakorn N, Sudhinaraset N, et al.  
393 Long-term specific IgG response to SARS-CoV-2 nucleocapsid protein in recovered  
394 COVID-19 patients. *Sci Rep* 2021;11(1):23216. Doi: 10.1038/s41598-021-02659-4.
- 395 19. Erikstrup C, Laksafoss AD, Gladov J, Kaspersen KA, Mikkelsen S, Hindhede L, et al.  
396 Seroprevalence and infection fatality rate of the SARS-CoV-2 Omicron variant in  
397 Denmark: A nationwide serosurveillance study. *Lancet Reg Health Eur* 2022;21:100479.  
398 Doi: 10.1016/j.lanpe.2022.100479.
- 399 20. Asamoah-Boaheng M, Goldfarb DM, Barakauskas V, Kirkham TL, Demers PA, Karim  
400 ME, et al. Evaluation of the Performance of a Multiplexed Serological Assay in the  
401 Detection of SARS-CoV-2 Infections in a Predominantly Vaccinated Population.  
402 *Microbiol Spectr* 2022;10(1):e0145421. Doi: 10.1128/spectrum.01454-21.

403

404

405

406

407

408

## 409 **Figures legends**

### 410 **Figure 1 Recruitment of participants.**

411

### 412 **Figure 2 Monthly distribution of SARS-CoV-2 variants and infection-induced**

413 **seroprevalence.** SARS-CoV-2 infection-induced seropositivity was identified by the

414 seropositivity of anti-N IgG or anti-RBD antibody for unvaccinated individuals and anti-N IgG

415 seropositivity or having reported of SARS-CoV-2 infection for vaccinated individuals with

416 BNT162b2 vaccine. Sera samples were collected from Thai children between January 2021 and

417 November 2022. Data on SARS-CoV-2 variants circulating during the study period was obtained

418 from a previous report [6]. The stacked bar graph represents the percentage of infection-induced

419 seropositivity according to vaccination status (see left Y-axis). Color shaded areas indicate the

420 number of positive samples of SARS-CoV-2 variants (see right Y -axis). The vertical dotted

421 lines indicate the quarter.

422

### 423 **Figure 3 Monthly distribution of seroprevalence induced by infection, vaccination, and**

424 **hybrid immunity observed in children aged 5-7 years old between January 2021 and**

425 **November 2022.** Seroprevalence induced by infection, vaccination, and hybrid immunity was

426 estimated based on the anti-RBD antibody seropositivity in both unvaccinated and vaccinated

427 participants.

428

## 429 **Supplementary Information**

430           **S1 Table. Baseline characteristics and data summaries of vaccination status and**  
431 **infection history.** The final study participants recruited from January to December 2021 (pre-  
432 omicron wave) and January to November 2022 (omicron-dominant wave). Sera samples were  
433 categorized according to the dates of blood collection into pre- and omicron dominant wave.  
434 Vaccination status was classify according to the dates of reported infection and vaccination.




Figure 1






Figure2




Figure3